Loading...

Xvivo Perfusion AB (publ)

XVIPYPNK
Healthcare
Medical - Specialties
$7.50
$-0.20(-2.60%)

Xvivo Perfusion AB (publ) (XVIPY) Stock Overview

Explore Xvivo Perfusion AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap945M
P/E Ratio43.89
EPS (TTM)N/A
ROE0.10%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$14.98

XVIPY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Xvivo Perfusion AB (publ) (XVIPY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $14.98.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 43.89 and a market capitalization of 945M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
37.63%
37.63%
Profit Growth
$6.48
87.52%
EPS Growth
$6.48
78.18%
Operating Margin
6.36%
2010.17%
ROE
10.14%
87.52%
Dividend Yield
0.00%
Analyst Recommendations data is not available for XVIPYAnalyst Recommendations details for XVIPY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

CEO

Christoffer Rosenblad

Employees

170

Headquarters

MAessans gata 10, Gothenburg

Founded

2022

Frequently Asked Questions

;